Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Cash (2016 - 2025)

Tandem Diabetes Care's Change in Cash history spans 13 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 106.5% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached $21.4 million, up 106.44%, while the annual FY2025 figure was $21.4 million, 106.44% up from the prior year.
  • Change in Cash reached -$1.3 million in Q4 2025 per TNDM's latest filing, down from $27.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $48.7 million in Q4 2022 to a low of -$51.1 million in Q3 2023.
  • Average Change in Cash over 5 years is -$198950.0, with a median of $2.2 million recorded in 2023.
  • The largest YoY upside for Change in Cash was 1974.14% in 2025 against a maximum downside of 14208.11% in 2025.
  • A 5-year view of Change in Cash shows it stood at -$41.2 million in 2021, then soared by 218.3% to $48.7 million in 2022, then crashed by 142.57% to -$20.7 million in 2023, then surged by 197.36% to $20.2 million in 2024, then plummeted by 106.5% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Change in Cash are -$1.3 million (Q4 2025), $27.8 million (Q3 2025), and $10.5 million (Q2 2025).